NEULAND LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of NEULAND LABORATORIES have increased by 30.84% YoY .
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 83.52 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
NEULAND LABORATORIES Last 5 Annual Financial Results
[BOM: 524558|NSE : NEULANDLAB]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,559 Cr | ₹1,191 Cr | ₹951 Cr | ₹937 Cr | ₹763 Cr |
| Expenses | ₹1,096 Cr | ₹919 Cr | ₹808 Cr | ₹790 Cr | ₹661 Cr |
| Operating Profit (Excl OI) | ₹463 Cr | ₹272 Cr | ₹143 Cr | ₹147 Cr | ₹102 Cr |
| Other Income | ₹13 Cr | ₹9.75 Cr | ₹2.08 Cr | ₹16 Cr | ₹3.89 Cr |
| Interest | ₹14 Cr | ₹13 Cr | ₹13 Cr | ₹18 Cr | ₹22 Cr |
| Depreciation | ₹60 Cr | ₹53 Cr | ₹49 Cr | ₹40 Cr | ₹31 Cr |
| Profit Before Tax | ₹401 Cr | ₹216 Cr | ₹82 Cr | ₹105 Cr | ₹53 Cr |
| Profit After Tax | ₹300 Cr | ₹164 Cr | ₹64 Cr | ₹81 Cr | ₹16 Cr |
| Consolidated Net Profit | ₹300 Cr | ₹164 Cr | ₹64 Cr | ₹81 Cr | ₹16 Cr |
| Earnings Per Share (Rs) | ₹233.89 | ₹127.45 | ₹49.74 | ₹62.85 | ₹12.63 |
| PAT Margin (%) | 19.25 | 13.73 | 6.71 | 8.61 | 2.13 |
| ROE(%) | 26.38 | 17.84 | 7.85 | 10.79 | 2.30 |
| ROCE(%) | 33.51 | 20.94 | 9.44 | 12.81 | 7.85 |
| Total Debt/Equity(x) | 0.06 | 0.12 | 0.28 | 0.22 | 0.37 |
Key Financials |
||
| Market Cap | : | ₹ 22,038.8 Cr |
| Revenue (TTM) | : | ₹ 1,528.3 Cr |
| Net Profit(TTM) | : | ₹ 279.7 Cr |
| EPS (TTM) | : | ₹ 218.5 |
| P/E (TTM) | : | 78.8 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| NEULAND LABORATORIES | 7.1% | 17.8% | 222.7% |
| SUN PHARMACEUTICAL INDUSTRIES | 2.8% | -2.7% | 50.6% |
| CIPLA | 2.9% | -1.2% | 25.5% |
| DR REDDYS LABORATORIES | 2.1% | -3.9% | 6.9% |
| ZYDUS LIFESCIENCES | 3.3% | -2% | 53.5% |
| DIVIS LABORATORIES | 3.5% | 5.4% | 67.6% |
| MANKIND PHARMA | 0.1% | -4% | 37.8% |
| TORRENT PHARMACEUTICALS | 4.3% | 5% | 59.6% |
| LUPIN | 3.7% | -4.8% | 65.6% |
NEULAND LABORATORIES Revenues
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 30.84 % |
| 5 Yr CAGR | 19.56 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,559 Cr | 30.84 | |
| Mar2023 | ₹1,191 Cr | 25.25 | |
| Mar2022 | ₹951 Cr | 1.51 | |
| Mar2021 | ₹937 Cr | 22.84 | |
| Mar2020 | ₹763 Cr | - | |
NEULAND LABORATORIES Operating Profit
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 70.17 % |
| 5 Yr CAGR | 45.97 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹463 Cr | 70.17 | |
| Mar2023 | ₹272 Cr | 90.61 | |
| Mar2022 | ₹143 Cr | -2.86 | |
| Mar2021 | ₹147 Cr | 44.10 | |
| Mar2020 | ₹102 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 30.06 % |
| 5 Yr CAGR | 22.09 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 29.68% | 30.06 | |
| Mar2023 | 22.82% | 52.13 | |
| Mar2022 | 15% | -4.28 | |
| Mar2021 | 15.67% | 17.29 | |
| Mar2020 | 13.36% | - | |
NEULAND LABORATORIES Profit After Tax
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 83.51 % |
| 5 Yr CAGR | 107.42 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹300 Cr | 83.51 | |
| Mar2023 | ₹164 Cr | 156.21 | |
| Mar2022 | ₹64 Cr | -20.85 | |
| Mar2021 | ₹81 Cr | 397.38 | |
| Mar2020 | ₹16 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 40.20 % |
| 5 Yr CAGR | 73.39 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 19.25 % | 40.20 | |
| Mar2023 | 13.73 % | 104.62 | |
| Mar2022 | 6.71 % | -22.07 | |
| Mar2021 | 8.61 % | 304.23 | |
| Mar2020 | 2.13 % | - | |
NEULAND LABORATORIES Earnings Per Share (EPS)
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 83.52 % |
| 5 Yr CAGR | 107.44 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹234 | 83.52 | |
| Mar2023 | ₹127 | 156.23 | |
| Mar2022 | ₹50 | -20.86 | |
| Mar2021 | ₹63 | 397.62 | |
| Mar2020 | ₹13 | - | |
NEULAND LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524558|NSE : NEULANDLAB]
| Y-o-Y | 60.03 % |
| 5 Yr CAGR | 43.74 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 33.51% | 60.03 | |
| Mar2023 | 20.94% | 121.82 | |
| Mar2022 | 9.44% | -26.31 | |
| Mar2021 | 12.81% | 63.18 | |
| Mar2020 | 7.85% | - | |
NEULAND LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹17,217.8 |
| Current MarketCap | : | ₹ 22,038.8 Cr |
| Updated EOD on | : | Dec 03,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | 7.1% |
17.8% |
222.7% |
| SENSEX | 1.1% |
1.1% |
22.2% |
NEULAND LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE SMALL CAP | 4.3% | 3.9% | 41.2% |
| S&P BSE MIDSMALLCAP | 3.5% | 2.9% | 40.4% |
| S&P BSE HEALTHCARE | 2.8% | 2.8% | 49.4% |
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
No NSE index found
You may also like the below Video Courses
FAQ about NEULAND LABORATORIES Financials
How the annual revenues of NEULAND LABORATORIES have changed ?
The Revenues of NEULAND LABORATORIES have increased by 30.84% YoY .
How the Earnings per Share (EPS) of NEULAND LABORATORIES have changed?
The Earnings Per Share (EPS) of NEULAND LABORATORIES has increased by 83.52 % YoY .
Check out Intrinsic Value of Peers of NEULAND LABORATORIES
Compare Stock Analytics of Peers of NEULAND LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
